June 3, 2021

Abbott Confirms Capacity to Support Expanded Use of HeartMate 3 Heart Pump

June 3, 2021—Abbott announced that the company has capacity and supply to effectively support the growing demand for mechanical circulatory support (MCS) devices for the effective treatment of advanced heart failure following Medtronic’s decision to stop the global distribution and sale of the Medtronic HeartWare ventricular assist device (HVAD).

Abbott is also supporting training and education programs for additional physicians who will now be offering Abbott’s HeartMate 3 heart pumps to their patients.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

June 3, 2021

Abbott Confirms Capacity to Support Expanded Use of HeartMate 3 Heart Pump

Current Issue

Keep In Touch